Advertisement

Table of contents

  1. Zheng Lu, Rüdiger Kaspera, Yoichi Naritomi, Tianli Wang
  2. Tanja Eisenblaetter, Lenore Teichert, Ronald Burnette, Paul Hutson
  3. Teodora Handjieva-Darlenska
  4. Gerd Bode, Petra Starck-Lantova
  5. Rainer Heissing, Anne-Ruth van Troostenburg
  6. M. Nikolova, R. Slavchov, G. Nikolova
  7. Federico Goodsaid, Felix Frueh, Michael E. Burczynski
  8. Lynne Hughes, Marie Trad, Stacey Boyer, Deborah Lee, Wei Yin
  9. Petar Nikolov, Georgi Banishki, Milena Nikolova-Vlahova
  10. Gulam Mohammed Husain, Mohammad Ahmed Khan, Mohd Urooj, Munawwar Husain Kazmi
  11. Smita Bhuyan, Sebastian Felgner, Dino Kocijancic, Vinay Pawar
  12. Jörg Schüttrumpf, Matthias Germer
  13. Pieter Siebenga, Pieter Okkerse, Guido van Amerongen, Robert Jan Doll, Alex Mentink, Justin Hay et al.
  14. Steven G. Woolfrey, James Gilmour Morrison
  15. Yichao Yu, Diether Rüppel, Willi Weber, Hartmut Derendorf
  16. Daniel F. B. Wright, Chihiro Hasegawa, Hesham S. Al-Sallami
  17. Jens Atzrodt, Volker Derdau, Claudia Loewe
  18. Andrew McEwen

About this book

Introduction

DDrug Discovery and Evaluation has become a more and more difficult, expensive and time-consuming process. The effect of a new compound has to be detected by in vitro and in vivo methods of pharmacology. The activity spectrum and the potency compared to existing drugs have to be determined.

As these processes can be divided up stepwise we have designed a book series "Drug Discovery and Evaluation" in the form of a recommendation document. The methods to detect drug targets are described in the first volume of this series "Pharmacological Assays" comprising classical methods as well as new technologies. Before going to man, the most suitable compound has to be selected by pharmacokinetic studies and experiments in toxicology. These preclinical methods are described in the second volume „Safety and Pharmacokinetic Assays". Only then are first studies in human beings allowed. Special rules are established for Phase I studies. Clinical pharmacokinetics are performed in parallel with human studies on tolerability and therapeutic effects. Special studies according to various populations and different therapeutic indications are necessary. These items are covered in the third volume: „Methods in Clinical Pharmacology".

For the 2nd edition, all the existing chapters will be revised and completely updated. A large number of assays were added. New chapters were included, such as pain, addiction, gene therapy, orphan diseases etc. etc. The complete work was new arranged.

Keywords

Assays drug action drugs clinical pharmacology pharmacodynamics pharmacokinetics

Editors and affiliations

  • Franz J. Hock
    • 1
  • Michael R. Gralinski
    • 2
  1. 1.CorDynamics DieburgGermany
  2. 2.CorDynamics ChicagoUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-319-56637-5
  • Copyright Information Springer Nature Switzerland AG 2018
  • Publisher Name Springer, Cham
  • eBook Packages Biomedical and Life Sciences
  • Online ISBN 978-3-319-56637-5
Industry Sectors
Pharma
Chemical Manufacturing
Biotechnology
Consumer Packaged Goods